Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
तुलना करने के लिए मीट्रिक्स | NVV1 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNVV1पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.7x | −0.5x | |
PEG अनुपात | 0.00 | 0.01 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 10.7x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 189.4% | 66.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 15.9% | 10.3% | अनलॉक करें |